Vascular endothelial growth factor A, long form · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Vascular endothelial growth factor A, long form shows approved-linked disease relevance led by wet macular degeneration. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P15692. Start with wet macular degeneration, then reuse UniProt P15692 as the stable protein anchor across project notes and exports.
Start with wet macular degeneration, then reuse UniProt P15692 as the stable protein anchor across project notes and exports.
Vascular endothelial growth factor A, long form shows approved-linked disease relevance led by wet macular degeneration. 5 more disease programs remain visible in the same review block. 9 linked drugs remain visible in the same block.
Start review with wet macular degeneration because it currently carries approved-linked support. Linked drugs include ABICIPAR PEGOL, AFLIBERCEPT, BEVACIZUMAB, BEVACIZUMAB GAMMA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyVascular endothelial growth factor A, long form
Review this target as Vascular endothelial growth factor A, long form, mapped to UniProt P15692. Sequence length is 395 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Vascular endothelial growth factor A, long form as ChEMBL target CHEMBL1783, mapped to UniProt P15692. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Vascular endothelial growth factor A, long form is the right protein anchor across sources, using UniProt P15692 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why wet macular degeneration is currently framed as approved-linked support. It currently carries 9 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Vascular endothelial growth factor A, long form |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P15692 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Vascular endothelial growth factor A, long form |
| UniProt Accession | P15692 |
| Component Type | Protein |
| Sequence Length | 395 aa |
Vascular endothelial growth factor A, long form
Review this target as Vascular endothelial growth factor A, long form, mapped to UniProt P15692. Sequence length is 395 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Vascular endothelial growth factor A, long form shows approved-linked disease relevance led by wet macular degeneration. 5 more disease programs remain visible in the same review block.
Start review with wet macular degeneration because it currently carries approved-linked support. Linked drugs include ABICIPAR PEGOL, AFLIBERCEPT, BEVACIZUMAB, BEVACIZUMAB GAMMA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3219623 | 10.6 | Kd | 0.025 | Preclinical |
| CHEMBL3219622 | 10.6 | Kd | 0.025 | Preclinical |
| CHEMBL3234202 | 9.92 | IC50 | 0.12 | Preclinical |
| CHEMBL3234200 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL2022564 | 9.49 | IC50 | 0.32 | Preclinical |
| CHEMBL3234201 | 9.33 | IC50 | 0.47 | Preclinical |
| CHEMBL604368 | 9.21 | Kd | 0.62 | Preclinical |
| CHEMBL325795 | 9.18 | Kd | 0.66 | Preclinical |
| CHEMBL590011 | 9.15 | Kd | 0.7 | Preclinical |
| CHEMBL604570 | 9.1 | Kd | 0.79 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 37 | 58 | 6.3 |
| single protein format | 16 | 236 | 6.6 |
| assay format | 5 | 100 | 6.8 |